Partial epigenetic reprogramming: the "holy grail" for aging therapeutics (Michael Ringel, Life Biosciences)

18 snips

Jun 4, 2025

Michael Ringel, COO of Life Biosciences and a seasoned expert with a PhD in biology, discusses groundbreaking advancements in cellular rejuvenation therapies. He delves into partial epigenetic reprogramming, dubbed the 'holy grail' for longevity, explaining how it rejuvenates cells while preserving functionality. The conversation touches on the promising ER-100 therapy aimed at combating vision loss and the collaborative spirit essential in biotech innovations. Ringel also emphasizes the potential of longevity interventions to tackle multiple age-related diseases simultaneously.

Ask episode

AI Snips

Chapters

Books

Transcript

Episode notes

INSIGHT

Life Biosciences' Unique Edge

Life Biosciences is leading the field with strong IP on the OSK factors and is the first to enter clinical trials for partial reprogramming.
Their approach uses OSK transcription factors, believed to deliver rejuvenation without tumor risk seen in full reprogramming.

INSIGHT

ER100 Eye Therapy Overview

Life's lead candidate ER100 delivers OSK to retinal ganglion cells via a single intravitreal injection.
In animal models including non-human primates, ER100 restored vision and improved optic nerve cell function after injury.

INSIGHT

ER100 Target Indications

ER100 targets glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), major age-related causes of blindness.
Existing treatments often fail late-stage patients, and no treatments exist for NAION, highlighting urgent unmet needs.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

Michael Ringel is the Chief Operating Officer of Life Biosciences, a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. Michael became COO of Life just a few months ago, but he's been advising the company since 2018. Prior to this year, he was managing director and senior partner at Boston Consulting Group (BCG), where over a 25-year career he focused on R&D and innovation initiatives across the private sector and government. He earned his PhD in biology at Imperial College London and a JD from Harvard Law, and has become an active and highly respected member of the global longevity biotech community.

In this episode, Chris and Michael explore Life Biosciences' groundbreaking approach to partial epigenetic reprogramming - the "holy grail" technology that could transform how we age at cellular, tissue, and organism levels. They discuss how this approach taps into the same biology that makes babies young, Life's lead therapeutic candidate ER-100 for eye diseases, and the "pipeline in a pill" concept at the core of the geroscience hypothesis: the idea that enable single interventions based on longevity science could treat multiple age-related diseases simultaneously.

The Finer Details:

The biology behind partial epigenetic reprogramming and how it differs from full reprogramming to pluripotency
Why Michael considers partial reprogramming the "holy grail" of longevity interventions
Life Biosciences' lead candidate ER-100 for glaucoma and NAION (non-arteritic anterior ischemic optic neuropathy)
The innovative inducible system that allows the therapy to be turned on and off with doxycycline
Why the eye represents an ideal starting point for reprogramming therapies
The "pipeline in a pill" concept and geroscience hypothesis - how single interventions could treat multiple age-related diseases
Parallels between the emerging longevity field and the massive GLP-1 drug market that many pharma companies missed
The role of philanthropic investment in advancing fundamental longevity research
Evolutionary theories of aging and why aging should be easily manipulable
Timeline expectations for moving from single disease treatments to whole-body rejuvenation

Links

Life Biosciences company website
Michael Ringel's ARDD talk